SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddy's gets nod to launch Zafirlukast

22 Nov 2010 Evaluate

Dr Reddy’s Laboratories has launched Zafirlukast tablets (10 mg and 20 mg), a bioequivalent generic version of Accolate in the US market.

Zafirlukast is a prescription medicine used for treating asthma. According to IMS Health, the medicine had total US sales of approximately $50 million for the 12 months ending August 31, 2010.On November 15, 2010, the US District Court of New Jersey granted Dr Reddy’s motion for summary judgment of non-infringement against AstraZeneca clearing the way for the launch of the product.

Subsequently, the Food & Drug Administration (FDA) approved Dr Reddy’s ANDA (abbreviated new drug application) for Zafirlukast tablets on November 18. The company’s tablets are available in bottles of 60 counts.crackcrack

Dr. Reddys Lab Share Price

1235.40 14.15 (1.16%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×